TNFRSF11B and breast carcinoma: While our previous data highlighted the potential for antiprogestogens for breast cancer prevention, the current data additionally support a clinical breast cancer prevention trial using denosumab to compensate for the low OPG levels throughout the menstrual cycle in BRCA-mutation carriers.